ALEXION PHARMACEUTICALS, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 1992-01-01
- Employees
- 3.8K
- Market Cap
- -
- Website
- http://www.alexion.com
Danicopan Early Access Program
- Conditions
- Paroxysmal Nocturnal HemoglobinuriaPNHExtravascular Hemolysis
- First Posted Date
- 2023-08-09
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT05982938
A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM)
Active, not recruiting
- Conditions
- Cardiomyopathy, DilatedBcl-2 Anathogene-3 (BAG3) Dilated Cardiomyopathy (DCM)
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT05981092
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
Recruiting
- Conditions
- Neuromyelitis Optica Spectrum DisorderNMOSDAQP4+ NMOSD
- First Posted Date
- 2023-07-28
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 122
- Registration Number
- NCT05966467
- Locations
- 🇺🇸
Research Site, Boston, Massachusetts, United States
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05886244
- Locations
- 🇨🇳
Research Site, Wuhan, China
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT05876351
- Locations
- 🇨🇳
Research Site, Wuhan, China
A Study to Investigate the Pharmacokinetic Profile of ALXN2050 Modified Release Prototype Formulations and Immediate Release Reference Tablet in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy Participants
- Interventions
- Drug: ALXN2050 MR Prototype TabletDrug: ALXN2050 Immediate Release (IR) TabletDrug: ALXN2050 MR Prototype Mini-Tablet
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05780645
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
Safety and Tolerability, Pharmacokinetic, and Pharmacodynamic Study of ALXN1920 in Healthy Participants
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT05751642
- Locations
- 🇳🇿
Research Site, Christchurch, New Zealand
🇳🇿Clinical Trial Site, Grafton, Auckland, New Zealand
ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE
Phase 3
Recruiting
- Conditions
- Cardiac DiseaseChronic Kidney DiseaseCKDCardiopulmonary Bypass
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 736
- Registration Number
- NCT05746559
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Potential Drug Interaction Between ALXN2040 and Rosuvastatin
- First Posted Date
- 2023-02-01
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT05708573
- Locations
- 🇺🇸
Clinical Trial Site, Baltimore, Maryland, United States
Early Access Program for ALXN1840 in Patients With Wilson Disease
- Conditions
- Wilson Disease
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2023-05-17
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Registration Number
- NCT05686564
© Copyright 2025. All Rights Reserved by MedPath